Tumour suppressor TRIM33 targets nuclear β-catenin degradation
2015 · Nature Communications · 154 citations
https://doi.org/10.1038/ncomms7156
K
Kangyu Lin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
135
Papers
2.8K
Citations
16
h-index
20
i10-index
Kangyu Lin is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer, Lipids, and Metabolism & Cancer, Hypoxia, and Metabolism. The author has an h-index of 16, co-authored 115 publications.
ORCID: 0000-0003-0140-2557Papers by this author
worksOncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression
2023 · Cancer Discovery · 106 citations
https://doi.org/10.1158/2159-8290.cd-22-1467
miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis
2016 · Cancer Research · 93 citations
https://doi.org/10.1158/0008-5472.can-15-3073
CRISPR–Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames
2023 · Nature Structural & Molecular Biology · 22 citations
https://doi.org/10.1038/s41594-023-01117-1
Identification of Colorectal Cancer Cell Stemness from Single-Cell RNA Sequencing
2023 · Molecular Cancer Research · 20 citations
https://doi.org/10.1158/1541-7786.mcr-23-0468
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
2016 · Journal of Hematology & Oncology · 15 citations
https://doi.org/10.1186/s13045-016-0241-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat